Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | International journal of hematology |
| MU Faculty or unit | |
| Citation | |
| Web | http://download.springer.com/static/pdf/372/art%253A10.1007%252Fs12185-015-1793-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12185-015-1793-1&token2=exp=1448961063~acl=%2Fstatic%2Fpdf%2F372%2Fart%25253A10.1007%25252Fs12185-015-17 |
| Doi | http://dx.doi.org/10.1007/s12185-015-1793-1 |
| Field | Oncology and hematology |
| Keywords | Immune thrombocytopenia; Thrombopoietin-receptor agonists; Remission; Sustained response |
| Attached files | |
| Description | Thrombopoietin-receptor agonists (TPO-RAs) are highly effective in immune thrombocytopenia (ITP). Recently, reports of sustained remission after TPO-RA discontinuation in adult ITP have been reported. We aimed to describe the subset of patients in whom TPO-RA therapy may induce a durable response. We retrospectively analyzed all of our adult ITP patients treated with TPO-RAs, and focused on patients with discontinued TPO-RA therapy due to treatment response. Forty-six relapsed or refractory ITP patients were treated with TPO-RAs. In 11 of these cases, TPO-RA therapy (seven romiplostim; four eltrombopag) was stopped after achieving treatment response. No side effects of TPO-RAs were observed. These patients were pretreated with 1-3 therapy lines plus splenectomy in six patients prior to TPO-RA administration. None of these patients experienced disease relapse after therapy discontinuation over a median follow-up of 33 months (16-54). Substantial proportion of ITP patients receiving TPO-RAs can maintain a durable response after treatment discontinuation. Sustained ITP remission probably does not depend on previous treatment, splenectomy, or disease duration. |
| Related projects: |